Medpace Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDP research report →
About the company
Medpace Holdings, Inc. , founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia.
- CEO
- August James Troendle
- IPO
- 2016
- Employees
- 5,900
- HQ
- Cincinnati, OH, US
Price Chart
- Market Cap
- $13.57B
- P/E
- 29.35
- P/S
- 5.07
- P/B
- 22.59
- EV/EBITDA
- 22.52
- Div Yield
- 0.00%
- Gross Margin
- 29.07%
- Op Margin
- 21.02%
- Net Margin
- 17.19%
- ROE
- 120.89%
- ROIC
- 56.06%
- Revenue
- $2.53B · 19.97%
- Net Income
- $451.12M · 11.56%
- EPS
- $15.64 · 19.75%
- Op Income
- $534.93M
- FCF YoY
- 19.15%
- 52W High
- $628.92
- 52W Low
- $294.07
- 50D MA
- $455.04
- 200D MA
- $512.68
- Beta
- 1.18
- Avg Volume
- 366.78K
Get TickerSpark's AI analysis on MEDP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Hansman Brad W. | other | 0 |
| Jun 1, 26 | Hansman Brad W. | other | 5,000 |
| Jun 1, 26 | Hansman Brad W. | other | 10,000 |
| May 28, 26 | EWALD STEPHEN P | other | 16,349 |
| May 28, 26 | EWALD STEPHEN P | sell | 16,349 |
| May 28, 26 | EWALD STEPHEN P | other | 16,349 |
| May 15, 26 | Zander Dani S. | other | 1,110 |
| May 15, 26 | McCarthy Cornelius P. III | other | 1,110 |
| May 15, 26 | Kraft Robert O. | other | 1,110 |
| May 15, 26 | Gwadry-Sridhar Femida H. | other | 1,110 |
Our MEDP coverage
Recent articles, reports, and earnings notes.
Medpace Holdings (MEDP): Growth Is Strong, Valuation Isn’t Cheap
Medpace is delivering fast revenue growth, strong backlog, and net cash, but the stock already prices in a lot of good news. The report leans constructive, with a selective Buy on pullbacks rather than an aggressive chase.
Medpace Holdings, Inc. (MEDP) slumps 17% on bookings miss
Medpace Holdings, Inc. (MEDP) slumps after hours despite a strong first quarter, as investors focus on weaker bookings and a sub-1.0x book-to-bill ratio. The company beat on revenue and earnings, but concerns about future demand and backlog growth drove the sharp selloff.
Medpace Holdings, Inc. (MEDP) Slumps After Q1 Beat
Medpace Holdings, Inc. (MEDP) slumps nearly 19% after hours after a Q1 earnings beat failed to impress investors. Strong revenue and EPS were overshadowed by softer bookings and guidance that did not raise expectations enough for a premium-valued CRO.
Want a deeper read on MEDP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.